STOCKNO.DE
Institutional ownership intelligence
Research
Schedule 13G/A

OCUL Schedule 13G/A filing by BlackRock

BlackRock reported beneficial ownership of 11.4M shares, representing 7.3% of OCULAR THERAPEUTIX INC in this filing.

FiledOct 22, 2024
Ownership dateSep 30, 2024
Reported shares11.4M
Reported ownership7.3%
Ownership details

Voting and dispositive power reported in the filing

These figures describe the reporting filer’s disclosed voting and investment authority. They should be read together with the reported share count and percentage.

Sole voting power 11.4M
Shared voting power 11.4M
Sole dispositive power 11.4M
Shared dispositive power 11.4M
Price context

Price dates alongside the ownership filing

Price data provides market context around the disclosure. It does not identify the filer’s actual transaction price.

Close near filing date$11.30as of Oct 22, 2024
Latest tracked price$8.64as of Aug 5, 2026
Source

Original filing and accession

Use the SEC filing as the primary source when you need the complete disclosure, footnotes, exhibits, or reporting-person details.

Reporting filer
BlackRock
CIK
CIK0002012383
Accession
0002012383-24-001626
Form
Schedule 13G/A
Open SEC filing View OCUL ownership history
Read the filing in context

Understand what a Schedule 13 filing does—and does not—tell you.

How to read a Schedule 13G → Does a 13G mean the shares were just bought? → Filing date vs. ownership date →